The current proposal represents a continuation of our investigation addressing the mechanisms of allograft rejection. We will concentrate on the ability of cellular components of the liver to stimulate an allograft response in order to better understand the mechanism(s) of liver allograft rejection and the potential for hepatocyte transplantation. These experiments will initially be undertaken in the murine models which have the benefit of l) well defined genetics 2) strong allograft responses 3) availability of immunodeficient animals 4) our familiarity with these models and techniques. Our ultimate goal, however, is to understand the mechanisms of human liver allograft rejection. To address the issue of the human response to alloantigen in vivo, investigators have had to study histology of grafts or to obtain cells or cytokines from peripheral blood or the local graft environment. The identification of recipient cells from the graft site requires in vitro growth and expansion of these cells. We feel the extension of our work into specific questions regarding the response of human cells to liver components requires the development of the SCID-hu model for transplantation studies. Tide development of a mouse reconstituted SCID (SCID-mu) is the logical first step in that process. The rationale for comparing the response of the SCID-mu to the intact host is that a) we can determine if the cellular response of the two are comparable in the face of rejection b) once we establish the cellular response seen in the SCID-mu as compared to the intact mouse we can omit cell populations considered nonessential for rejection in the reconstitution. This may help define cells that are essential for rejection c) similarly, differences in cytokine profiles in the face of rejection can help in the determination of essential cytokines for rejection. These areas will be the focus of future work. The SCID-hu and SCID-mu will enable us to study the host response to specific parenchymal cells in the absence of in vitro culture artifacts which has been shown to select for specific clones of donor reactive cells. Additionally, we hope to use the model to define the human response to human liver. These studies are designed to determine the local and systemic cellular and cytokin immune response to liver components. Furthermore, the trafficking patterns of immunocompetent cells in these models will be established.
AIM I : Determine the influence of MHC antigen expression on in vitro and in vivo alloreactivity to components of the murine liver.
AIM II : Development of the mouse reconstituted SCID model (SCID-mu) for transplantation studies.
AIM III : Determine the murine cellular and cytokine response to cellular elements of the murine liver using the SCID- mu model as compared to the intact BALB/c host.
AIM I V: Development of the SCID-hu model for transplantation studies.
AIM V : Determine the human cellular and cytokine response to cellular elements of human liver.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI028284-06
Application #
2064350
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Project Start
1988-09-30
Project End
1995-09-29
Budget Start
1993-09-30
Budget End
1995-09-29
Support Year
6
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Surgery
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Wacher, V J; Liu, T; Roberts, J P et al. (1995) Time course of cyclosporine and ist motabolites in blood, liver and spleen of naive Lewis rats: comparison with preliminary data obtained in transplanted animals. Biopharm Drug Dispos 16:303-12
Osorio, R W; Ascher, N L; Melzer, J S et al. (1994) beta-2 Microglobulin gene disruption prolongs murine islet allograft survival in NOD mice. Transplant Proc 26:752
Osorio, R W; Ascher, N L; Melzer, J S et al. (1994) Enhancement of islet allograft survival in mice treated with MHC class I specific F(ab')2 alloantibody. Transplant Proc 26:749
Osorio, R W; Ascher, N L; Stock, P G (1994) Prolongation of in vivo mouse islet allograft survival by modulation of MHC class I antigen. Transplantation 57:783-8
Martinez, O M; Villanueva, J C; Lake, J et al. (1993) IL-2 and IL-5 gene expression in response to alloantigen in liver allograft recipients and in vitro. Transplantation 55:1159-66
Osorio, R W; Ascher, N L; Jaenisch, R et al. (1993) Isolation of functional MHC class I-deficient islet cells. Transplant Proc 25:968-9
Osorio, R W; Ascher, N L; Jaenisch, R et al. (1993) Major histocompatibility complex class I deficiency prolongs islet allograft survival. Diabetes 42:1520-7
Martinez, O M; Ascher, N L; Ferrell, L et al. (1993) Evidence for a nonclassical pathway of graft rejection involving interleukin 5 and eosinophils. Transplantation 55:909-18
Krams, S M; Ascher, N L; Martinez, O M (1993) New immunologic insights into mechanisms of allograft rejection. Gastroenterol Clin North Am 22:381-400
Freise, C E; Clemmings, S; Clemens, L E et al. (1991) Demonstration of local immunosuppression with methylprednisolone in the sponge matrix allograft model. Transplantation 52:318-25

Showing the most recent 10 out of 11 publications